fashion -WSS

fashion

author：focus 2025-10-04 03:59:47 - browse：9252

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： NASA releases new images of 'fingerprint

leisure time

explore

WSS

Abbott's new stent may help patients with peripheral artery disease

EU climate chief is concerned over the expansion of the coal industry in China

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Trump pressured former Arizona governor to overturn 2020 election results: Sources

Obesity drug from Roche shows promise in early study

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Alkermes shareholders re

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Duchenne breakthrough therapy leaves behind pioneering families

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Activists slam private health insurers over coverage restrictions

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

The high cost of giving birth even with insurance

US judge blocks portions of new Florida elections law

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

hotspot

The White House hikes tariffs on plastic syringes made in China

A timeline of the missing Titanic tourist submersible

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

STAT series 'Denied by AI' wins major journalism prizes

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

leisure time

leisure time

explore

focus